Hans Veit Coester

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

Christoph Kapitza, Thomas Först, Hans Veit Coester et al. · Diabetes Obesity and Metabolism · 2013 · 189 citations · Full text

Steady state is reached within 2–3 days of once‐daily administration of degludec, a basal insulin with an ultralong duration of action

Tim Heise, Stefan Korsatko, Leszek Nosek et al. · Journal of Diabetes · 2015 · 44 citations

Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

Tim Heise, Leszek Nosek, Oliver Klein et al. · Diabetes Obesity and Metabolism · 2015 · 23 citations

Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults

Paula Persson, Anne-Beth Amstrup, Hans Veit Coester et al. · Research and Practice in Thrombosis and Haemostasis · 2023 · 22 citations · Full text

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

L. Bergougnan, Grit Andersen, Leona Plum‐Mörschel et al. · British Journal of Clinical Pharmacology · 2020 · 13 citations · Full text